ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

(2017) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

(2017) You-cai Zhu et al.   OncoTargets and Therapy

Non–Small Cell Lung Cancer

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Transformation ofALKrearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib

(2016) N. Takegawa et al.   ANNALS OF ONCOLOGY

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non–Small-cell Lung Cancer

(2016) Alexios Matikas et al.   Clinical Lung Cancer

Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy

(2016) Samer Tabchi et al.   INVESTIGATIONAL NEW DRUGS

A Case of ALK- Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

(2016) Yoon Jin Cha et al.   Journal of Thoracic Oncology

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib

(2016) Shiro Fujita et al.   Journal of Thoracic Oncology

Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma

(2016) Charline Caumont et al.   LUNG CANCER

Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors

(2016) Delphine Levacq et al.   LUNG CANCER

Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma

(2016) Shi-Yu Jiang et al.   MEDICINE

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

(2015) Matthew G Oser et al.   LANCET ONCOLOGY

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

(2015) Matthew J. Niederst et al.   Nature Communications

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

(2015) Hideko Isozaki et al.   Cancers

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY